Camlin Fine Sciences / Q4-FY26

Read the quarter in context.

A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

Watch2026-05-15Back to CAMLINFINE

Revenue

₹425 Cr

verified against source

Revenue YoY

reported change

EBITDA

Pending

latest reported figure

Source

screener in

record provenance

Actual signal trajectory

Where this quarter sits.

source records only
PAT (₹ Cr)PositiveWatchNegative
1 actual records
Actual quarterly PAT (₹ Cr) trajectoryReported values plotted by quarter. Hover or focus a point for its quarter, value, and source sentiment.Q4 FY26: 86 · Watch source sentiment · 2026-05-15Q4 FY268686
Values are taken from the available verified source records; sentiment color is a separate source-read indicator.

Quarter read

What the record says.

Camlin Fine Sciences reported FY26 revenue of ₹1,723 crore, impacted by ~20% shipment delays due to geopolitical disruptions. The blends business grew 17% (18% including discontinued Europe), missing the 20% target due to Winpai liquidity issues. Vanillin realizations improved to $12.5/kg in Q4 from $11, with tariffs reduced to 15.5% in the US. Management maintained FY27 guidance of ₹2,200-2,400 crore revenue and 12-14% EBITDA margins, driven by vanillin volumes of 4,000-4,200 MT and blends scaling to ₹1,400 crore. Key risks include lingering logistics disruptions, rising raw material costs (phenol up from ₹85 to ₹150/kg), and potential cash flow stress from extended working capital cycles.

Colored figures show movement against the previous available record.

Guidance to track

  • Management expects consolidated revenue between ₹2,200 and ₹2,400 crore for FY27, driven by vanillin volume recovery and blends growth.
  • Management targets EBITDA margins of 12-14% for FY27, supported by vanillin margin improvement and cost control.
  • Blends revenue is expected to cross ₹1,400 crore in FY27, with Winpai and Beta4 turning EBITDA positive.
  • Management expects vanillin sales volume of 4,000-4,200 MT in FY27, with US volumes of 2,200-2,400 MT.

Risks flagged

  • Geopolitical tensions have extended shipping times to 40-50 days and tripled freight costs, impacting working capital and sales execution.
  • Phenol prices have surged from ₹85 to ₹150/kg due to the conflict, increasing vanillin production costs by ~$1.5-2/kg.
  • Longer delivery times and liquidity crunch at Winpai have strained cash flows; management may need additional debt or equity.
  • Solvay is pricing vanillin at $17-18/kg to gain market share, limiting Camlin's ability to raise prices despite tariff reductions.

Key quotes

  • We are not changing our guidance for FI27. We're guiding on the same line.
  • Our bigger challenge is of course the longer working capital cycles and logistics and cash flow. So that's what we need to address.
  • We have a large order book even in all our businesses actually and executing that with tight cash flow position is a bigger challenge than the market itself.

Research modules

Go one layer deeper.